Ask Warren

Rznomics

476830 · KOSDAQ · ₩476830 · 알지노믹스

₩21,300▼ ₩1,350 (5.96%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −52.67%
Market cap
₩600B
Enterprise value
₩565B
P/E
—
P/B
12.9×
Dividend yield
0.0%
ROE
−42.6%
Net margin
−990.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−82.6% from the high

₩19,990Today: ₩20,600 – ₩22,400₩122,630

Returns

  • 1W−9.4%
  • 1M−11.4%
  • 3M−11.8%
  • 6M−75.8%
  • YTD−73.5%
  • 1Y—
Volume today
300,728
0.9× the 20-day average
Traded today
₩6.4B
Listed shares
28,184,335
EPS (12 months)
−₩704
Earnings yield −3.3%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.IPOListed Dec 18, 2025 at ₩22,500IPO details →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Why is it moving?

−6.0% on Oct 30, 2026.

Rznomics is mentioned in a Money Today article comparing its strategy with several other Korean materials companies. The article is a general comparison, and the sources give no clear news about the company's business today.

AI summary of the news and filings linked. It can be wrong; check them.

  • • Foreign investors bought a net ₩405M that day

Possible reasons, not certainties. Not financial advice.

Signals

41Quiet
  • BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
  • MomentumWeak-10.7% over the last month; the price is below its 20-day average.
  • News impactLow6 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 30: sell ₩508M at the close (6.1% of 20-day average trading value)

Oct 1Last 20 trading days (% of average trading value)Oct 30

On its 37 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 7.3% of trading value and pointed the same way 31 of 37 times.

  • 2× KODEX KOSDAQ150 Leverage −₩438M
  • -1× KODEX KOSDAQ150 Futures Inverse −₩30M
  • 2× TIGER KOSDAQ150 Leverage −₩28M
  • 2× RISE KOSDAQ150 Futures Leverage −₩8.2M
  • -1× TIGER KOSDAQ150 Futures Inverse −₩1.5M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

Rznomics stock overview

Rznomics (알지노믹스, KRX: 476830) is listed on KOSDAQ, in the Biotech & Pharma sector. The text provided is only a glossary of technical terms (RNA trans-splicing, gene therapy, drug discovery stages, and clinical trial terminology) and does not describe the company's business overview, products, customers, or locations, so no summary can be drawn from it. Its shares closed at ₩21,300 on Oct 30, 2026, down 5.96% on the day, giving it a market value of ₩600B.

Key facts

Market cap
₩600B
Sector
Biotech & Pharma
Latest price change
−5.96%
As of
Oct 30, 2026
Main business
The text provided is only a glossary of technical terms (RNA trans-splicing, gene therapy, drug discovery stages, and clinical trial terminology) and does not describe the company's business overview, products, customers, or locations, so no summary can be drawn from it.

Quick answers about Rznomics

What does Rznomics do?
The text provided is only a glossary of technical terms (RNA trans-splicing, gene therapy, drug discovery stages, and clinical trial terminology) and does not describe the company's business overview, products, customers, or locations, so no summary can be drawn from it.
What is the market cap of Rznomics?
The market capitalisation of Rznomics was ₩600B at the close on Oct 30, 2026.
Who are the largest shareholders of Rznomics?
According to the latest official filings, the largest reported holders are Lee Seong-wook (23.87%, as of Oct 15, 2026); Korea Development Bank (6.21%, as of Sep 9, 2026); KB Investment (4.85%, as of Dec 26, 2025).
When is the next earnings report from Rznomics?
Korean companies rarely announce results dates in advance. Based on when Rznomics filed the same report in past years, its next 3q results is expected between Nov 11, 2026 and Nov 14, 2026.
Does the National Pension Service own Rznomics?
Yes. The National Pension Service held 3.96% of Rznomics shares as of Jul 1, 2026.

Company profile

The text provided is only a glossary of technical terms (RNA trans-splicing, gene therapy, drug discovery stages, and clinical trial terminology) and does not describe the company's business overview, products, customers, or locations, so no summary can be drawn from it.

Written by AI from the company's latest annual report.

Korean name
알지노믹스
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
CEO
이성욱
Founded
Aug 2017
Listed
Dec 2025
Listed shares
28,184,335
Fiscal year ends
Month 12
Website
www.rznomics.com/

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Rznomics / 알지노믹스 / 476830 / KRX:476830

Source: KRX statistical information